Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Switching to Ezetimibe/Simvastatin vs Doubling Statin Dose in Hospitalized Coronary Patients
NCT00132717Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jan 2005
- Primary completion
- Jun 2007
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, randomised, open-label trial of Vytorin in hypercholesterolemia (2 arms), sponsored by Organon & Co. Primary endpoint: Low-Density Lipoprotein Cholesterol at 12 weeks. Started Jan 2005; status: completed.
02
Drugs
Vytorin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00132717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132717.